StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The significant rise in stock price (122.18%) reflects positive investor sentiment after favorable trial results, akin to other biotech stocks experiencing similar boosts from effective trial data.
What happened, with direct paths to the underlying reporting
PepGen shares surged 122.18% to $5.91 amid high trading volume. FREEDOM-DM1 trial shows 53.7% splicing correction at 15 mg/kg dose. All patients at 15 mg/kg showed improved treatment response. Upcoming results from FREEDOM2-DM1 MAD expected in Q1 2026. Company raised $100 million through a share offering at $3.20.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.